Firstkind Announce Gold Sponsorship of CLOT (Clinical Leaders of Thrombosis)

Share Article

Firstkind Ltd is delighted to announce its gold sponsorship of CLOT (Clinical Leaders of Thrombosis). CLOT is a special interest group which unites multi-disciplinary healthcare professionals working in the field of Haemostasis and Thrombosis.

News Image

The geko™ device

Dr Indira Natarajan, Royal Stoke University Hospital comments, “The geko™ device is a new paradigm in antithrombotic therapy for acute stroke."

Firstkind Ltd is delighted to announce its gold sponsorship of CLOT (Clinical Leaders of Thrombosis). CLOT is a special interest group which unites multi-disciplinary healthcare professionals working in the field of Haemostasis and Thrombosis. They support their members to deliver high quality care to patients through shared best practice and experience to advance healthcare delivery.    

Andrew Thelwell, Firstkind’s CCO comments “Our gold sponsorship reflects a shared vision with CLOT to reduce venous thrombosis in hospitalised patients through quality care and best practice. At Firstkind we are partnering with healthcare professionals passionate to embrace innovation in their forward thinking to help solve challenging medical problems. In the area of venous thromboembolism (VTE) prevention we have collaborated with the NHS Royal Stoke Hospital to introduce the innovative geko™ device into the acute stroke pathway for patients for whom other methods of deep vein thrombosis (DVT) prevention are contraindicated or impractical. Now in routine use, the geko™ device was introduced through an audit of clinical practice, which has led to a significant change in nursing practice”.

Jodie Williams, Clinical Nurse Specialist at the Royal Stoke University Hospital, UHNM NHS Trust says, “The audit has proven the geko™ device as well tolerated and its introduction has marked a significant change in our VTE nursing practice on the acute stroke ward. The device is easy to fit and patients are much easier to mobilize. We now routinely check that patients are fitted with either the geko™ device or intermittent pneumatic compression (IPC) on our wards rounds. These checks provide confidence that all at-risk acute stroke patients are compliant with one of the available mechanical VTE interventions at all times”.

Dr Indira Natarajan, Consultant Stroke Physician and Clinical Director of Neurosciences at the Royal Stoke University Hospital, UHNM NHS Trust comments, “The geko™ device is a new paradigm in antithrombotic therapy for acute stroke. The clinical audit has revealed that we are aligned to the CLOTS 3 study which reports as many as 36% of patients are contraindicated or become intolerant to IPC. It is to this unmet need cohort that we now routinely fit the geko™ device, and this has ensured that all acute stroke patients can now receive VTE prophylaxis, where previously no prophylaxis was given”.

The geko™ is a battery powered, disposable, neuromuscular electrostimulation device designed to increase blood flow in the deep veins of the leg. The geko™ gently stimulates the common peroneal nerve activating the calf and foot muscle pumps increasing venous, arterial and microcirculatory blood flow. The blood flow increase is equal to 60% of walking, without a patient having to move or exert energy.

Current UK practice for DVT prophylaxis, in acute stroke, is based upon data from the CLOTS 3 study and routinely comprises of IPC or a prophylactic-dose of Low Molecular Weight Heparin (LMWH), when the bleed risk is reduced. However, regardless of the merits of these interventions, a large number of patients remain contraindicated to these therapies leaving them exposed to developing a DVT or PE (Pulmonary Embolism).

The Royal Stoke clinical audit assessed patient compliance and the geko™ anti-stasis capability in patients admitted for either ischemic or haemorrhagic stroke. Patients unsuitable for VTE drug prophylaxis or contraindicated to IPC were prescribed the geko™ device.

About Firstkind and Sky Medical Technology Ltd

Sky Medical Technology, the parent of Firstkind Ltd, is a highly innovative UK based medical devices company that has developed a ground-breaking neuromuscular electrostimulation technology platform, OnPulse®. The company develops a range of products tailored to the needs of different medical application areas selling both direct and through strategic partnerships or distributors in each major clinical area. Clinical areas of interest include oedema control, DVT prevention, wound healing and elite sport recovery. The goal in each clinical area is to improve clinical outcomes and patient care whilst saving health system resources.

For more information visit: http://www.gekodevices.com

About CLOT

The diverse professional membership includes nurses, pharmacists, doctors, biomedical scientists and other allied healthcare professionals.

The growing network of members work in a variety of specialist settings including:-

  •     Anticoagulation & DVT Services
  •     Use of the DOAC's
  •     Thrombophilia
  •     Thromboprophylaxis
  •     Allied services
  •     General practice

For more information please visit: http://www.clotuk.com/

About North Midlands NHS Trust

The stroke service is jointly provided by University Hospitals of North Midlands NHS Trust and the Staffordshire and Stoke on Trent Partnership Trust. They have a combined acute stroke unit (hyper-acute beds and acute beds) and a specialist stroke rehabilitation unit at Haywood Hospital.

For more information visit: http://www.uhnm.nhs.uk/OurServices/pages/Stroke.aspx

Media contact:

Sue Davenport
+44 (0)1494 572044
Sky Medical Technology Limited
Hawk House
Peregrine Business Park
Gomm Road
High Wycombe
Buckinghamshire
HP13 7DL
United Kingdom

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sue Davenport
@gekorecovery
since: 07/2014
Follow >
Visit website

Media